Chemomab (CMMB) Director Neil Cohen Sells 2,304 Shares

What Happened

• Neil Cohen, a director of Chemomab Therapeutics Ltd. (CMMB), reported two open‑market sales: 1,304 shares on 2026-08-27 at $2.85 ($3,716) and 1,000 shares on 2026-08-28 at $2.80 ($2,800), for total proceeds of $6,516.
• The filing also reports previously granted derivative awards (stock options) covering 18,075 shares granted across 2020–2026; those option grants show $0 acquisition price in the report because they are awards/option grants (derivatives).

Key Details

• Transaction types: S = Sale (open market) on 2026-08-27 and 2026-08-28; A = Award/Grant (derivative option holdings from 2020–2026).
• Sale details: 1,304 shares @ $2.85 (Aug 27) = $3,716; 1,000 shares @ $2.80 (Aug 28) = $2,800; total ≈ $6,516.
• Derivative holdings: options totaling 18,075 shares (grants dated 7/16/2020; 4/19/2021; 3/7/2022; 3/21/2023; 3/18/2024; 3/16/2025; 3/16/2026). Footnotes F1–F6 state these options are fully vested and exercisable as of the report date.
• No 10b5‑1 plan, cashless exercise, tax‑withholding sale, or gift is indicated in the provided data.
• Filing: Report filed 2026-09-01 for transactions dated 2026-08-27 and 2026-08-28. The provided data does not flag the filing as late.

Context

• Sales by directors are often routine (liquidity or portfolio reasons); they do not by themselves indicate the director’s view of the company. Purchases tend to be more informative for signaling.
• The reported A (derivative) rows are option awards/grants (fully vested and exercisable) — they represent the right to acquire shares, not immediate purchases of common stock. There is no indication in this filing that options were exercised and shares sold concurrently.